Actionable news
All posts from Actionable news
Actionable news in ANIP: ANI Pharmaceuticals, Inc.,

Ani Pharmaceuticals Appoints Peter A. Lankau To Its Board Of Directors

The following excerpt is from the company's SEC filing.

BAUDETTE, Minn., Oct. 13, 2015 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) announced today the appointment of Peter A. Lankau to the Company's Board of Directors to fill the existing vacancy in the Board. Mr. Lankau has over 30 years of management experience in developing and commercializing pharmaceutical products.

Mr. Lankau is a principal in the consulting firm, Lankau Consulting LLC, which provides advisory and consulting services to support boards of directors and senior management of pharmaceutical and biotechnology companies, as well as venture capital and private equity firms. He is Chairman of the Board of Phosphagenics Limited, an Australian research-based biotechnology company. Prior to that, Mr. Lankau was Executive Chairman at Nautilus Neurosciences, Inc., a private neurology-focused specialty pharmaceutical company. Prior to Nautilus, Mr. Lankau was Chairman and CEO of Logical Therapeutics, Inc., a venture backed, development stage biopharmaceutical company, and was President, Chief Executive Officer and Director of Endo Pharmaceuticals Inc., a publicly traded specialty pharmaceutical company. Mr. Lankau also currently serves on the Board of Advisors of Orchard Venture Partners, a life sciences venture capital firm.

Robert E. Brown, Jr., Chairman of ANI, commented: "We are delighted that Peter Lankau has joined the ANI Board of Directors. Peter's broad and deep experience in the specialty pharmaceutical industry makes him an ideal fit for ANI. We very much look forward...